- In July 2025, India’s ICMR–RMRC Bhubaneswar issued an Expression of Interest for licensing its new recombinant multi-stage malaria vaccine, AdFalciVax, designed to prevent Plasmodium falciparum infection and reduce community transmission. This initiative aims to partner with manufacturers for development and commercialization of this technology
- In December 2024, a pre-clinical and Phase 1 clinical study demonstrated that a monovalent recombinant protein vaccine (RBD XBB.1.5‑HR) provided strong safety and immunogenicity against Omicron XBB‑lineage variants—including JN.1 and EG.5.1—in both animal models and humans
